,index,Rank,Acronym,ArmGroupDescription,ArmGroupInterventionName,ArmGroupLabel,ArmGroupType,BriefSummary,BriefTitle,CentralContactEMail,CentralContactName,CentralContactRole,CompletionDate,CompletionDateType,Condition,ConditionBrowseLeafAsFound,ConditionMeshId,ConditionMeshTerm,DesignAllocation,DesignInterventionModel,DesignMasking,DesignObservationalModel,Rank,DesignPrimaryPurpose,DesignTimePerspective,DesignWhoMasked,DetailedDescription,DispFirstPostDate,DispFirstPostDateType,DispFirstSubmitDate,DispFirstSubmitQCDate,EligibilityCriteria,EnrollmentCount,EnrollmentType,EventGroupDeathsNumAffected,EventGroupDeathsNumAtRisk,EventsFrequencyThreshold,EventsTimeFrame,FDAAA801Violation,Gender,HealthyVolunteers,IPDSharing,InterventionArmGroupLabel,Rank,InterventionDescription,InterventionName,InterventionOtherName,InterventionType,IsFDARegulatedDrug,LastKnownStatus,LastUpdatePostDate,LastUpdatePostDateType,LastUpdateSubmitDate,LeadSponsorClass,LeadSponsorName,LocationCity,LocationContactEMail,LocationContactName,LocationCountry,LocationFacility,LocationState,LocationStatus,MaximumAge,MinimumAge,Rank,NCTId,OfficialTitle,OrgClass,OrgFullName,OtherEventStatsNumAffected,OtherEventStatsNumAtRisk,OtherEventStatsNumEvents,OtherEventTerm,OtherOutcomeDescription,OtherOutcomeMeasure,OtherOutcomeTimeFrame,OutcomeAnalysisCILowerLimit,OutcomeAnalysisCINumSides,OutcomeAnalysisCIPctValue,OutcomeAnalysisCIUpperLimit,OutcomeAnalysisDispersionType,OutcomeAnalysisDispersionValue,OutcomeAnalysisPValue,OutcomeAnalysisParamType,OutcomeAnalysisParamValue,Rank,OutcomeAnalysisStatisticalMethod,OutcomeClassDenomCountValue,OutcomeDenomCountValue,OutcomeDenomUnits,OutcomeGroupDescription,OutcomeGroupTitle,OutcomeMeasureDescription,OutcomeMeasureDispersionType,OutcomeMeasureParamType,OutcomeMeasurePopulationDescription,OutcomeMeasureReportingStatus,OutcomeMeasureTimeFrame,OutcomeMeasureTitle,OutcomeMeasureType,OutcomeMeasurementValue,OutcomeMeasureUnitOfMeasure,OutcomeMeasurementLowerLimit,OutcomeMeasurementSpread,OutcomeMeasurementUpperLimit,OverallOfficialAffiliation,Rank,OverallOfficialName,OverallOfficialRole,OverallStatus,OversightHasDMC,Phase,PointOfContactEMail,PointOfContactOrganization,PointOfContactTitle,PrimaryCompletionDate,PrimaryCompletionDateType,PrimaryOutcomeDescription,PrimaryOutcomeMeasure,PrimaryOutcomeTimeFrame,ReferenceCitation,ReferencePMID,ResponsiblePartyInvestigatorAffiliation,ResponsiblePartyInvestigatorFullName,ResponsiblePartyInvestigatorTitle,ResponsiblePartyType,ResultsFirstPostDate,Rank,ResultsFirstPostDateType,ResultsFirstSubmitDate,ResultsFirstSubmitQCDate,SamplingMethod,SecondaryId,SecondaryIdType,SecondaryIdDomain,SecondaryIdLink,SecondaryOutcomeDescription,SecondaryOutcomeMeasure,SecondaryOutcomeTimeFrame,SeriousEventAssessmentType,SeriousEventNotes,SeriousEventStatsNumAffected,SeriousEventStatsNumAtRisk,SeriousEventStatsNumEvents,SeriousEventTerm,StartDate,StartDateType,StatusVerifiedDate,Rank,StdAge,StudyFirstPostDate,StudyFirstPostDateType,StudyFirstSubmitDate,StudyFirstSubmitQCDate,StudyPopulation,StudyType,VersionHolder,WhyStopped,Placebo
187,187,188,,"ML-004 is a bilayer immediate-release (IR)/extended-release (ER, gastroretentive) oral tablet formulation. ML-004 is taken orally once daily and provided as a tablet in two dose strengths of 12 mg (3 mg IR/9 mg ER) and 24 mg tablet (6 mg IR/18 mg ER). Dose levels for this study are 12 mg (provided as one 12 mg tablet), 24 mg (one 24 mg tablet), 48 mg (two 24 mg tablets), and 72 mg (three 24 mg tablets).|Matched placebo oral tablets will consist of same excipients as the investigational drug but without any ML-004. Placebo taken orally once daily to match tablet number of ML-004 dose levels for 12 mg (1 tablet), 24 mg (1 tablet), 48 mg (2 tablets), and 72 mg (3 tablets).",Drug: ML-004 (IR)/(ER) tablet|Drug: ML-004 Placebo,ML-004 (IR)/(ER) tablet|ML-004 Placebo,Experimental|Placebo Comparator,"ML-004-002 is a multi-center, randomized, double-blind, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD",ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD),,,,"December 31, 2023",Anticipated,Autism Spectrum Disorder,Autism|Autism Spectrum Disorder|Autism Spectrum Disorder,D000004194|D000001321|D000067877|D000002659,"Disease|Autistic Disorder|Autism Spectrum Disorder|Child Development Disorders, Pervasive",Randomized,Parallel Assignment,Triple,,188,Treatment,,Participant|Care Provider|Investigator,"ML-004-002 is a Phase 2, multi-center, randomized, double-blind, placebo- controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective of the study will be to evaluate the efficacy of ML-004 compared with placebo for the treatment of care/study partner-reported social communication deficits in patients with ASD.||Subjects will be randomized to study treatment in a 1:1 ratio of ML-004: placebo.||Treatment will begin with 2 weeks of once daily dosing of ML-004 or placebo followed by a 9-12 day dose-titration phase until the maximum allowable tolerated dose (based on subject weight) is reached. The maximum dose tolerated during dose titration will become the maintenance dose (MD) for that subject, and the subject will remain on this dose for 12 weeks, followed by a down titration. An independent DSMC will monitor trial progress and ensure that the safety of trial subjects is not compromised.",,,,,"Inclusion Criteria:||Age 12 to 45 at screening|Has a designated care/study partner who can reliably report on symptoms|Has a diagnosis of Autism Spectrum Disorder (ASD)|Full scale IQ (or equivalent) ≥70 score|Psychoactive medications and adjunctive therapies are stable for 4 weeks prior to screening|Must be able to swallow study medication||Exclusion Criteria:||Has Rett syndrome or Child Disintegrative Disorder|Has participated in any other study and received any other investigational medication (other than COVID-19 vaccination) or device within 60 days prior to screening|History of epilepsy without current adequate control, or any seizure in the 6 months preceding screening|History of suicidal ideation or behavior in the past 12 months, or a positive response to C-SSRS questions 4 and/or 5|Systolic blood pressure ≥160 mmHg, or diastolic blood pressure ≥100, or a clinical history of uncontrolled or severe hypertension|If female, is pregnant or lactating",150.0,Anticipated,,,,,,All,No,Undecided,ML-004 (IR)/(ER) tablet|ML-004 Placebo,188,Participants will receive ML-004 once daily for up to 16 weeks.|Participants will receive matching placebo once daily for up to 16 weeks,ML-004 (IR)/(ER) tablet|ML-004 Placebo,,Drug|Drug,Yes,,"October 18, 2021",Actual,"October 5, 2021",INDUSTRY,MapLight Therapeutics,,,,,,,,45 Years,12 Years,188,NCT05081245,"A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).",INDUSTRY,MapLight Therapeutics,,,,,,,,,,,,,,,,,188,,,,,,,,,,,,,,,,,,,,,188,,,Not yet recruiting,Yes,Phase 2,,,,"August 10, 2023",Anticipated,Change from baseline in the ABI-Social Communication Domain Score will be reported. The ABI is a 62-item questionnaire for reporting the behaviors of subjects (ages: 3 years-adulthood) diagnosed with ASD. The tool is suitable for completion by parents or care/study partners of people with ASD. Each item assesses either quality (from not at all to without help) or frequency (never to very often) of a particular behavior. The Social Communication domain score is the sum of the scores in the social communication domain divided by the number of items in the domain.,Change from Baseline in Autism Behavior Inventory (ABI)-Social Communication Domain Score,Baseline up to Day 110,,,,,,Sponsor,,188,,,,,,,,,"The CGI-I score is a single-item instrument based on a 7-point scale routinely used in clinical trials to capture the Investigator's global impression of response. The Investigator or designee rates the improvement observed from 1 (very much improved) to 7 (very much worse).|The ABI-Clinician (ABI-C) captures the clinician rating of behaviors of a person with ASD that occurred over the week prior to assessment. It contains 14 items reflecting the core and associated autism behavior domains: Social Communication, Restrictive Behaviors, Mood and Anxiety, Self Regulation, and Challenging Behavior. Each item is rated on a 7-point scale from 1 (none; no symptoms present) to 7 (very severe; persistent interference with function or adaptation).|The ABC is a parent- or care/study partner-reported behavior rating assessment with five domains and 58 items, each rated on a 0 (not a problem) to 3 (the problem is severe in degree) scale. The irritability domain consists of 15 items.|The CGI-S is a global assessment of the clinician-rater's impression of the severity of the participant's illness. It is rated on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill).|Each item on the ABI-Repetitive/Restrictive Behavior Domain is rated by frequency (0=never to 3=very often). The domain score is the sum of all domain items scores divided by the number of items in the domain.|Each item on the ABI- Mood and Anxiety Domain is rated by frequency (0=never to 3=very often). The domain score is the sum of all domain items scores divided by the number of items in the domain.|Each item on the ABI- Challenging Behavior Domain is rated by frequency (0=never to 3=very often). The domain score is the sum of all domain items scores divided by the number of items in the domain.|Each item on the ABI- Self-regulation Domain is rated by frequency (0=never to 3=very often). The domain score is the sum of all domain items scores divided by the number of items in the domain.|The ABI-S is a 24-item short version of the ABI, containing items from each of the five domains. The domain score for each domain is calculated as the sum of scores all domain items divided by the number of items in the domain.|The ABC-SW subscale consists of 16 items of the ABC-2 rated from 0 (not a problem) to 3 (the problem is severe in degree).|The SRS-2 consists of 65 items across 5 subscales. Responses range from 1 (not true) to 4 (almost always true).|The Vineland-3 Domain Level Version contains 5 domains. Responses on each item are rated from 0 (never) to 2 (usually).","Change from Baseline in Clinician Global Impression of Improvement (CGI-I)|Change from Baseline in Autism Behavior Inventory-Clinician (ABI-C) Score|Change from Baseline in Aberrant Behavior Checklist 2-Irritability (ABC-I) Subscale Score|Change from baseline in the Clinician Global Impression of Severity (CGI-S) Score|Change from baseline in the ABI Repetitive/Restrictive Behavior Domain Score|Change from baseline in the ABI Mood and Anxiety Domain Score|Change from baseline in the ABI Challenging Behavior Domain Score|Change from baseline in the ABI Self-regulation Domain Score|Change from baseline in the ABI-Short Form (ABI-S) Score|Change from baseline in the ABC-Social Withdrawal (ABC-SW) Subscale Score|Change from baseline in the Social Responsiveness Scale 2 (SRS-2) Score|Change from baseline in the Vineland-3 (Domain Level Version) Score: total of Communication, Socialization, and Maladaptive behavior domains",Day 110|Baseline up to Day 110|Baseline up to Day 110|Baseline up to Day 110|Baseline up to Day 110|Baseline up to Day 110|Baseline up to Day 110|Baseline up to Day 110|Baseline up to Day 110|Baseline up to Day 110|Baseline up to Day 110|Baseline up to Day 110,,,,,,,"November 15, 2021",Anticipated,October 2021,188,Child|Adult,"October 18, 2021",Actual,"October 5, 2021","October 5, 2021",,Interventional,"November 09, 2021",,Yes
1401,401,1402,TSC-STEPS,Sirolimus|Placebo,Drug: Sirolimus|Drug: Placebo,Sirolimus|Placebo,Experimental|Placebo Comparator,"This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.",Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study,info@tscsteps.org,"Molly S Griffith, BA",Contact,"June 30, 2026",Anticipated,Tuberous Sclerosis Complex|Epilepsy,Sclerosis|Epilepsy|Tuberous Sclerosis|Tuberous Sclerosis Complex,D000014402|D000004827|D000012598,Tuberous Sclerosis|Epilepsy|Sclerosis,Randomized,Parallel Assignment,Triple,,1402,Prevention,,Participant|Care Provider|Investigator,"Tuberous Sclerosis Complex (TSC) is caused by genetic mutation in TSC1 or TSC2, resulting in dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway. Age at time of seizure onset in TSC infants has been linked to long-term neurodevelopmental outcome in this high-risk population. Sirolimus is an mTOR inhibitor used to treat many of the symptoms of TSC, including epilepsy. This will be the first study to truly evaluate a targeted, disease-modifying drug therapy for preventing or delaying seizure onset in TSC using a rational, mechanism-based therapeutic approach.",,,,,"Inclusion Criteria:||0-6 months of age at the time of enrollment (subject must be <7 months of chronological age at time of randomization and treatment initiation). Corrected age must be at least 39 weeks (calculated by subtracting the number of weeks born before 40 weeks gestation from the chronological age).|Has a confirmed diagnosis of TSC based on established clinical or genetic criteria||Exclusion Criteria:||Prior history of seizures (clinical or electrographic) at the time of enrollment or identified on baseline EEG.|Has been treated in the past or is currently being treated at the time of enrollment with conventional anticonvulsant medications (AEDs), systemic (oral) mTOR inhibitors (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, or another anti-seizure therapeutic agent, device, or procedure.|Has taken any other investigational drug as part of another research study, within 30 days prior to the baseline screening visit.|Has a significant illness or active infection at the time of the baseline screening visit|Has a history of significant prematurity, defined as gestational age <30 weeks at the time of delivery, or other significant medical complications at birth or during the neonatal period that other than TSC would convey additional risk of seizures or neurodevelopmental delay (i.e. HIE, severe neonatal infection, major surgery, prolonged ventilatory or other life-saving supportive care or procedures).|Abnormal laboratory values at baseline (i.e., renal function, liver function, or bone marrow production) that are in the opinion of the investigator clinically significant and may jeopardize the safety of the study subject.|Prior, planned or anticipated neurosurgery within 3 months of the baseline visit|Has a TSC-associated condition for which mTOR treatment is clinically indicated (i.e. SEGA or AML).|Subjects who are, in the opinion of the investigator, unable to comply with the requirements of the study.",64.0,Anticipated,,,,,,All,No,,Sirolimus|Placebo,1402,"The investigational drug product to be used in this study is sirolimus, provided in oral suspension.|Matching placebo",Sirolimus|Placebo,,Drug|Drug,Yes,,"November 3, 2021",Actual,"October 22, 2021",OTHER,Darcy Krueger,Birmingham|Los Angeles|Palo Alto|Boston|Saint Louis|Chapel Hill|Cincinnati|Houston,jessicakrefting@uabmc.edu|angelamartinez@mednet.ucla.edu|jwinter2@stanford.edu|emine.arcasoy@childrens.harvard.edu|novako@wustl.edu|hannah.riehl@cidd.unc.edu|molly.griffith@cchmc.org|saba.usmani@uth.tmc.edu,"Jessica Krefting, RN|E. Martina Bebin, MD, MPA|Angela Martinez|Rajsekar Rajamaran, MD, MS|Jennifer Winterbottom|Brenda Porter, MD|Emine Arcasoy|Mustafa Sahin, MD, PhD|Olga Novak|Michael Wong, MD, PhD|Hannah Riehl|Jamie Capal, MD|Molly S Griffith, BA|Darcy A Krueger, MD, PhD|Saba Usmani|Hope Northrup, MD",United States|United States|United States|United States|United States|United States|United States|United States,University of Alabama at Birmingham|University of California at Los Angeles|Stanford University|Boston Children's Hospital|Washington University -- St. Louis|University of North Carolina at Chapel Hill|Cincinnati Children's Hospital Medical Center|University of Texas HSC at Houston,Alabama|California|California|Massachusetts|Missouri|North Carolina|Ohio|Texas,Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting,6 Months,,1402,NCT05104983,Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study,OTHER,"Children's Hospital Medical Center, Cincinnati",,,,,,,,,,,,,,,,,1402,,,,,,,,,,,,,,,,,,,,"Children's Hospital Medical Center, Cincinnati|University of Alabama at Birmingham",1402,"Darcy A Krueger, MD, PhD|Martina Bebin, MD, MPA",Principal Investigator|Principal Investigator,Recruiting,Yes,Phase 2,,,,"June 30, 2025",Anticipated,"Time to seizure onset, comparing sirolimus with placebo|Percentage of subjects reporting severe (CTCAE v5.0 grade >= 3) adverse event (AE) or serious adverse event (SAE), comparing sirolimus with placebo.",Efficacy -- time to seizure onset|Safety -- adverse events,12 months of age|12 months of age,,,"Children's Hospital Medical Center, Cincinnati",Darcy Krueger,IND Sponsor/Lead Principal Investigator,Sponsor-Investigator,,1402,,,,,1R01FD007275,U.S. FDA Grant/Contract,,https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01FD007275&Fy=all,"Neurodevelopmental outcomes at the end of treatment, comparing sirolimus with placebo.|Patient and caregiver quality of life, comparing sirolimus with placebo.|EEG measures of neuronal connectivity, comparing sirolimus with placebo.|MRI measures of neuronal connectivity, comparing sirolimus with placebo.|Validate the feasibility and effectiveness of sirolimus precision dosing in infants with TSC",Neurodevelopmental Outcomes|Quality of Life Outcomes|EEG Biomarkers|MRI Biomarkers|Sirolimus Precision Dosing,12 and 24 months of age|12 and 24 months of age|12 and 24 months of age|12 and 24 months of age|12 months of age,,,,,,,"October 13, 2021",Actual,October 2021,1402,Child,"November 3, 2021",Actual,"October 22, 2021","October 22, 2021",,Interventional,"November 09, 2021",,Yes
